title: [Administration of polysaccharide K (PSK) for stage III colorectal cancer in clinical practice].
abstract: OBJECTIVE
  This retrospective study was performed to evaluate the administration and effect of PSK in patients with stage III colorectal cancer in clinical practice.
  
  
  METHODS
  The subjects were 55 patients with stage III colorectal cancer who received adjuvant chemotherapy, comprising UFT in 44, UFT/calcium folinate (Leucovorin) in 4 and 5-FU/levofolinate calcium (l-LV) in 7, between April 2000 and December 2006. The rate of administering PSK, disease-free survival time, and overall survival time were evaluated.
  
  
  RESULTS
  The rate of administering PSK was 82%. There was no significant difference in disease-free survival and overall survival between patients who received PSK and those without. Among the patients in stage IIIa, the patients who received PSK tended to show a longer overall survival time than those without PSK (p =0.15).
  
  
  CONCLUSIONS
  The rate of administering PSK is high in patients with stage III colorectal cancer. But further cases would be needed to evaluate the effect of PSK with 5-FU-based adjuvant chemotherapy.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyazaki
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Moriyuki
authors.initials: M
authors.lastname: Matsuki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011134:Polysaccharides / Q000008:administration & dosage* / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D011134:Polysaccharides